Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 101–200 of 1,008
Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases
Brudvik, K. W., Kopetz, S. E., Li, L., Conrad, C., Aloia, T. A., & Vauthey, J.-N. (2015) · British Journal of Surgery · doi:10.1002/bjs.9870 · Cited by 214
Colorectal Cancer Biomarkers: Where Are We Now?
Gonzalez-Pons, M., & Cruz-Correa, M. (2015) · BioMed Research International · doi:10.1155/2015/149014 · Cited by 209
“However, recent studies have reported compelling evidence that, in addition to KRAS, mutations in NRAS predict nonresponse to anti-EGFR therapy [26, 27].”
BackgroundA multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
Schell, M. J., Yang, M., Teer, J. K., Lo, F. Y., Madan, A., Coppola, D., Monteiro, A. N. A., Nebozhyn, M. V., Yue, B., Loboda, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11743 · Cited by 207
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Cai, W.-Q., Zeng, L.-S., Wang, L.-F., Wang, Y.-Y., Cheng, J.-T., Zhang, Y., Han, Z.-W., Zhou, Y., Huang, S.-L., Wang, X.-W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01249 · Cited by 196
“Other studies have shown that panitumumab was ineffective in patients with NRAS mutations (59).”
BackgroundDistinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
García-Foncillas, J., Sunakawa, Y., Aderka, D., Wainberg, Z., Ronga, P., Witzler, P., & Stintzing, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00849 · Cited by 201
“In PRIME, panitumumab in combination with FOLFOX4was shown to have greater benefit in aRASwt-targeted patient population rather than in a patient population identified as KRAS wt, compared with FOLFOX4 alone (65).”
BackgroundResultModest, D. P., Martens, U. M., Riera-Knorrenschild, J., Greeve, J., Florschütz, A., Wessendorf, S., Ettrich, T., Kanzler, S., Nörenberg, D., Ricke, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01340 · Cited by 193
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
Heinemann, V., Stintzing, S., Modest, D. P., Giessen-Jung, C., Michl, M., & Mansmann, U. R. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.116 · Cited by 185
“A retrospective analysis of data from the multicenter, open-label, phase III PRIME trial, investigating panitumumab plus FOLFOX-4 versus FOLFOX-4 alone first-line in patients with mCRC [12,37,38] evaluated tumour response at week 8 in 584 randomised patients with KRASwt tumours according to RECIST (version 1.”
BackgroundMethodMartinelli, E., Martini, G., Famiglietti, V., Troiani, T., Napolitano, S., Pietrantonio, F., Ciardiello, D., Terminiello, M., Borrelli, C., Vitiello, P. P., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2915 · Cited by 182
Pietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182
“In particular, anti-EGFR therapy is nowadays approved for subjects with RAS wild-type tumors (1-3).”
BackgroundPeeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181
“For panitumumab, our results in the second-line setting are consistent with those from a previous prospective– retrospective RAS analysis of the PRIME study (which evaluated Percent tumor shrinkage from baseline; positive values indicate reduction in tumor size, whereas negative values indicate an increase in tumor si…”
BackgroundMethodResultInfluentialSelf-citationHerpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00359-0 · Cited by 178
Self-citationSepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0554-cp · Cited by 172
Mohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., Pichler, M., Gerger, A., Eisner, F., Hoefler, G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004271 · Cited by 177
“Furthermore, other RAS mutations than KRAS exon 2 mutations have recently been discussed as predictive markers [37].”
BackgroundPragmatic issues in biomarker evaluation for targeted therapies in cancer
de Gramont, A., Watson, S., Ellis, L. M., Rodón, J., Tabernero, J., de Gramont, A., & Hamilton, S. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.202 · Cited by 176
Self-citationHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01140-9 · Cited by 173
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Boussios, S., Ozturk, M., Moschetta, M., Karathanasi, A., Zakynthinakis-Kyriakou, N., Katsanos, K., Christodoulou, D., & Pavlidis, N. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010012 · Cited by 168
“Among several major genetic mutations in CRC, the RAS mutational status (KRAS or NRAS mutations in exons 2, 3, or 4) has been recognized as an important biomarker able to predict response to anti-EGFR antibodies [13].”
BackgroundThe current understanding on the impact of KRAS on colorectal cancer
Meng, M., Zhong, K., Jiang, T., Liu, Z., Kwan, H. Y., & Su, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111717 · Cited by 171
Schirripa, M., Bergamo, F., Cremolini, C., Casagrande, M., Lonardi, S., Aprile, G., Yang, D., Marmorino, F., Pasquini, G., Sensi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.142 · Cited by 172
“During the last decade, the assessment of RAS and BRAF mutational status gained increasing importance for an optimal management of CRC (Schmoll et al, 2012; Douillard et al, 2013).”
BackgroundSystematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles
Kim, E., Ilic, N., Shrestha, Y., Zou, L., Kamburov, A., Zhu, C., Yang, X., Lubonja, R., Tran, N., Nguyen, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0160 · Cited by 169
Möhrmann, L., Huang, H. J., Hong, D. S., Tsimberidou, A. M., Fu, S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., Naing, A., Krug, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2007 · Cited by 166
“Clin Cancer Res; 24(1) January 1, 2018 Clinical Cancer Research 182”
BackgroundInfluentialJones, R. P., Sutton, P. A., Evans, J. P., Clifford, R., McAvoy, A., Lewis, J., Rousseau, A., Mountford, R., McWhirter, D., & Malik, H. Z. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.37 · Cited by 166
Schirripa, M., Cremolini, C., Loupakis, F., Morvillo, M., Bergamo, F., Zoratto, F., Salvatore, L., Antoniotti, C., Marmorino, F., Sensi, E., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.28955 · Cited by 166
“Left colon 129 (48) 161 (42) 16 (36) 9 (13)”
First-line chemotherapy for mCRC—a review and evidence-based algorithm
Cremolini, C., Schirripa, M., Antoniotti, C., Moretto, R., Salvatore, L., Masi, G., Falcone, A., & Loupakis, F. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.129 · Cited by 162
Peeters, M., Kafatos, G., Taylor, A., Gastanaga, V. M., Oliner, K. S., Hechmati, G., Terwey, J.-H., & van Krieken, J. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.017 · Cited by 163
Self-citationArdini, E., Bosotti, R., Borgia, A. L., De Ponti, C., Somaschini, A., Cammarota, R., Amboldi, N., Raddrizzani, L., Milani, A., Magnaghi, P., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.001 · Cited by 157
Self-citationAcquired resistance to EGFR‐targeted therapies in colorectal cancer
Van Emburgh, B. O., Sartore-Bianchi, A., Di Nicolantonio, F., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 160
Self-citationAfrăsânie, V.-A., Marinca, M. V., Alexa-Stratulat, T., Gafton, B., Păduraru, M., Adavidoaiei, A. M., Miron, L., & Rusu, C. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0033 · Cited by 159
Laurent-Puig, P., Pekin, D., Normand, C., Kotsopoulos, S. K., Nizard, P., Perez-Toralla, K., Rowell, R., Olson, J., Srinivasan, P., Le Corre, D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0983 · Cited by 157
“However, except for extended RAS mutations (10), none of the candidate genes get through clinical validation.”
BackgroundCremolini, C., Bartolomeo, M. D., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv290 · Cited by 173
Self-citationYoon, H. H., Tougeron, D., Shi, Q., Alberts, S. R., Mahoney, M. R., Nelson, G. D., Nair, S. G., Thibodeau, S. N., Goldberg, R. M., Sargent, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3140 · Cited by 156
“tional RAS activating mutations that predict a lack of response to panitumumab (49, 50).”
Taieb, J., Zaanan, A., Le Malicot, K., Julié, C., Blons, H., Mineur, L., Bennouna, J., Tabernero, J., Mini, E., Folprecht, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5225 · Cited by 154
Self-citationCancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
Martinelli, E., Morgillo, F., Troiani, T., & Ciardiello, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.001 · Cited by 146
“The only known catalytic substrates for both MEK1/2 isoforms are the MAP kinases ERK1 and ERK2 [4-25].”
BackgroundInfluentialDoubly blind: a systematic review of gender in randomised controlled trials
Phillips, S. P., & Hamberg, K. (2016) · Global Health Action · doi:10.3402/gha.v9.29597 · Cited by 155
“Douillard (industry) (32) Comparison of new and conventional treatments for colorectal cancer based on genetic markers Outcomes were associated with presence of gene mutations N 620 Women 30% Age 18 Documented race, ethnicity Elkenboom (industry) (33) Comparison of dabigatran and warfarin in patients with mechanical h…”
BackgroundOkita, A., Takahashi, S., Ouchi, K., Inoue, M., Watanabe, M., Endo, M., Honda, H., Yamada, Y., & Ishioka, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24617 · Cited by 155
“RAS mutation is a biomarker for predicting resistance to anti-epidermal growth factor receptor (anti-EGFR) antibodies, and its status is essential for determining the therapeutic indication of anti-EGFR antibodies [6–9].”
Imamura, Y., Lochhead, P., Yamauchi, M., Kuchiba, A., Qian, Z. R., Liao, X., Nishihara, R., Jung, S., Wu, K., Nosho, K., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-135 · Cited by 151
“In addition, a recent published study reported by Douillard et al., showed that RAS mutants (N = 108) with any mutation in KRAS codons 61, 117 and 146, or NRAS codons 12, 13, 61, 117 and 146, did not benefit from combined panitumumab plus FOLFOX4 chemotherapy [29].”
BackgroundMethodInfluentialSchmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152
“…of RAS, so-called expanded RAS, to include KRAS and NRAS codons 12, 13, 59, 61, 117, 146 can more precisely identify patients with mCRC for anti-EGFR therapy than KRAS codons 12 and 13 testing alone (Bokemeyer et al., 2014; Douillard et al., 2013; Heinemann et al., 2014; Peeters et al., 2014).”
BackgroundMolecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 152
Brudvik, K. W., Mise, Y., Chung, M. H., Chun, Y. S., Kopetz, S., Passot, G., Conrad, C. H., Maru, D. M., Aloia, T. A., & Vauthey, J. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5187-2 · Cited by 158
Towards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 165
Normanno, N., Rachiglio, A. M., Lambiase, M., Martinelli, E., Fenizia, F., Esposito, C., Roma, C., Troiani, T., Rizzi, D., Tatangelo, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv176 · Cited by 157
“Approximately 60% of mCRC metastatic colorectal carcinoma (mCRC) carries mutations in either KRAS or NRAS genes that determine resistance to anti-EGFR monoclonal antibodies [3-5].”
BackgroundMolecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.001 · Cited by 155
“This recommendation is supported by evidence from one randomized controlled trial, reported by Douillard et al.(44) This report used prospective patient data collected within the PRIME trial.”
BackgroundMethodResultInfluentialMorkel, M., Riemer, P., Bläker, H., & Sers, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4750 · Cited by 144
“Upon treatment with EGFR-inhibiting antibodies such as Cetuximab or Panitumumab, patients showed an overall survival benefit of 3–5 months when the cancer was wildtype for KRAS, but no benefit when the cancer was KRAS-mutated [92–94].”
MethodCatenacci, D. V. T. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 144
“(Yap et al., 2012; Gerlinger et al., 2012) Although the challenge of imposing a biopsy in ‘real time’ had been prohibitive over that last decade, (Dowlati et al., 2001) recently, this is becoming more accepted and even required for biomarker stratified trial enrollment.”
BackgroundRole of bile acids in colon carcinogenesis
Nguyen, T. T., Ung, T. T., Kim, N. H., & Jung, Y. D. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i13.577 · Cited by 143
Management of colorectal cancer
Stintzing, S. (2014) · F1000Prime Reports · doi:10.12703/p6-108 · Cited by 190
“Furthermore, in patients with a RAS mutant tumor, the combination of oxaliplatin and an anti-EGFR antibody had the detrimental effect of shorter OS [65,67] than chemotherapy alone.”
BackgroundMolecular Pathology of Colorectal Cancer
Harada, S., & Morlote, D. M. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000247 · Cited by 171
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
Participation of the Elderly Population in Clinical Trials: Barriers and Solutions
Denson, A. C., & Mahipal, A. (2014) · Cancer Control · doi:10.1177/107327481402100305 · Cited by 138
Microbial markers in colorectal cancer detection and/or prognosis
Villéger, R., Lopès, A., Véziant, J., Gagnière, J., Barnich, N., Billard, E., Boucher, D., & Bonnet, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i22.2327 · Cited by 158
Stintzing, S., Miller‐Phillips, L., Modest, D. P., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.023 · Cited by 152
“A detrimental effect of anti-EGFR agents has, however, only been observed when oxaliplatin-containing chemotherapies were used [6,23].”
BackgroundSystemic Therapy for Colon Cancer
Wu, C. S.-Y. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.11.001 · Cited by 151
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
van Oordt, C. W. M. D. H., Gootjes, E. C., Huisman, M. C., Vugts, D. J., Roth, C., Luik, A. M., Mulder, E. R., Schuit, R. C., Boellaard, R., Hoekstra, O. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4672 · Cited by 147
“Patients with mCRC harboring a K-RAS mutation [3–5] or N-RAS mutation [6] do not respond to anti-EGFR treatment.”
Cathomas, G. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00035 · Cited by 133
“Several clinical trials have shown that RAS mutations are the most important negative predictive factor in CRC, primarily mutations in exon 1 and 2 of RAS, but, as recently been shown, also of exon 3 and 4 of KRAS and NRAS, respectively (32, 33).”
BackgroundMolecular phenotypes of colorectal cancer and potential clinical applications
Kocarnik, J. M., Shiovitz, S., & Phipps, A. I. (2015) · Gastroenterology Report · doi:10.1093/gastro/gov046 · Cited by 132
“studies have now shown that KRAS testing restricted to exon 2 misses 15–17% of cases resistant to anti-EGFR therapy [68, 69].”
BackgroundRivera, F., Karthaus, M., Hecht, J. R., Sevilla, I., Forget, F., Fasola, G., Canon, J.-L., Guan, X., Demonty, G., & Schwartzberg, L. S. (2017) · International Journal of Colorectal Disease · doi:10.1007/s00384-017-2800-1 · Cited by 135
“BRAF mutation status has emerged as a strong prognostic marker [12] but there is a lack of evidence to support best”
BackgroundMethodResultInfluentialSelf-citationRaghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00226 · Cited by 132
Morris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132
“Additionally, greater understanding of the molecular pathways driving survival and proliferation of colorectal tumor cells has led to the approval of novel targeted therapies—namely, cetuximab and panitumumab—specifically tailored to inhibit epidermal growth factor receptor (EGFR) pathways and thereby thwart tumor gro…”
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer
Petty, R., Dahle-Smith, Å., Stevenson, D. A. J., Osborne, A., Massie, D., Clark, C., Murray, G. I., Dutton, S., Roberts, C., Chong, I. Y.-S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3934 · Cited by 142
“This is analogous to non–small-cell lung cancer and colorectal adenocarcinoma in which EGFR mutation and KRAS mutation, respectively, have provided useful predictive biomarker tests and allowed subgroups to be defined as responsive to antiEGFR therapies.(27,28) We aimed to determine if analysis of EGFR signaling pathw…”
BackgroundMolecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives
Geng, F., Wang, Z., Yin, H., Yu, J., & Cao, B. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2210 · Cited by 131
“25–29 Panitumumab is a fully humanized monoclonal antibody.”
Current Targeted Therapy for Metastatic Colorectal Cancer
Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 149
Maron, S. B., Alpert, L., Kwak, H. A., Lomnicki, S., Chase, L., Xu, D., O'Day, E., Nagy, R. J., Lanman, R. B., Cecchi, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1260 · Cited by 124
“79 II 0 (0) 11 (8) III 1 (13) 29 (22) IV 7 (88) 88 (67) Unknown 0 (0) 1 (1)”
KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis
Formica, V., Sera, F., Cremolini, C., Riondino, S., Morelli, C., Arkenau, H.-T., & Roselli, M. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab190 · Cited by 120
Shitara, K., Muro, K., Watanabe, J., Yamazaki, K., Ohori, H., Shiozawa, M., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02791-w · Cited by 138
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
“Somatic activating mutations in KRAS or NRAS are present in up to 52% of colorectal cancer (CRC) [1, 2], causing constitutive activation of the RAF/ MEK/ERK signaling pathway independent of upstream receptor tyrosine kinases like the epidermal growth factor receptor (EGFR).”
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Tournigand, C., Chibaudel, B., Samson, B., Scheithauer, W., Vernerey, D., Mésange, P., Lledo, G., Viret, F., Ramée, J., Tubiana-Mathieu, N., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00216-8 · Cited by 140
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 146
Tosi, F., Magni, E., Amatu, A., Mauri, G., Bencardino, K. B., Truini, M., Veronese, S. M., Carlis, L. G. D., Ferrari, G. C., Nichelatti, M., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.004 · Cited by 137
Self-citationStage IV Colorectal Cancer Management and Treatment
Dominguez, O. H., Yılmaz, S., & Steele, S. R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12052072 · Cited by 135
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2887 · Cited by 121
“In addition to chemotherapy, patients with RAS wildtype tumors may receive either anti–epidermal growth factor receptor (EGFR) or anti–vascular endothelial growth factor (VEGF) –directed agents.(1-6) Both strategies were compared in two randomized phase III trials: FIRE-3 (FOLFIRI as chemotherapy backbone) and CALGB 8…”
BackgroundWasan, H. S., Meade, A. M., Adams, R., Wilson, R. H., Pugh, C., Fisher, D. J., Sydes, B., Madi, A., Sizer, B., Lowdell, C. P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70106-8 · Cited by 134
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121
“Expanded RAS mutations in KRAS exon 3 or 4, or inNRAS exon 2, 3, or 4 have also been noted to predict a lack of benefit from EGFRi, increasing the prevalence of all innate RAS mutations to 50% to 55% (8, 13, 14).”
BackgroundLi, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
“Although the use of cetuximab and panitumumab has greatly improved the overall survival (OS) and other clinical outcomes of mCRCs [4, 5], some patients cannot benefit from it.”
BackgroundGong, J., Cho, M. T., Sy, M., Salgia, R., & Fakih, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15030 · Cited by 123
“This is also consistent with recent data from the PRIME and CRYSTAL clinical trials, where exon 3 and 4 KRAS and exons 2, 3, and 4 NRAS mutations reflected 14-17% of RAS mutations [8, 9].”
ResultZanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010445 · Cited by 117
“Response to cetuximab in “quadruple negative” mCRC xenopatients: A population study in 125 cases Clinical studies have recently demonstrated that, in addition to the validated KRAS mutations in exon 2, additional KRAS mutations in exons 3 and 4, as well as NRAS, BRAF, and concurrent PIK3CA (exon 20) mutations, predict…”
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu230 · Cited by 116
“9% of cases, a frequency similar to other studies, such as PRIME, PEAK, and FIRE-3 trials, in which no NRAS exon 4 mutations were as well identified [6, 13, 14].”
ResultSorbye, H., Dragomir, A., Sundström, M., Pfeiffer, P., Thunberg, U., Bergfors, M., Aasebø, K., Eide, G. E., Ponten, F., Qvortrup, C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131046 · Cited by 115
“In wtKRAS/BRAF patients we found longer PFS in 3rd-line treatment.”
BackgroundResultInfluentialHecht, J. R., Cohn, A. L., Dakhil, S. R., Saleh, M. N., Piperdi, B., Cline-Burkhardt, M., Tian, Y., & Go, W. Y. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.009 · Cited by 128
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer
Sinicrope, F. A., Okamoto, K., Kasi, P. M., & Kawakami, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.02.008 · Cited by 116
Morano, F., Corallo, S., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Murialdo, R., Zaniboni, A., Sartore-Bianchi, A., Tomasello, G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01254 · Cited by 111
Seligmann, J. F., Elliott, F., Richman, S. D., Jacobs, B., Hemmings, G., Brown, S., Barrett, J. H., Tejpar, S., Quirke, P., & Seymour, M. T. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6065 · Cited by 113
Pietrantonio, F., Morano, F., Corallo, S., Miceli, R., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Bergamo, F., Sartore-Bianchi, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1467 · Cited by 113
von Einem, J. C., Heinemann, V., von Weikersthal, L. F., Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1678-3 · Cited by 112
“…this population comprises about 50 % of all patients with mCRC with a benefit in median OS following egFR-targeted first-line therapy of 5–7 months (Douillard et al. 2013; Stintzing et al. 2009). taking into account that even RaS wild-type tumors potentially do not define the perfect marker for…”
BackgroundInfluentialZoratto, F., Rossi, L., Verrico, M., Papa, A., Basso, E., Zullo, A., Tomao, L., Romiti, A., Russo, G. L., & Tomao, F. (2014) · Tumor Biology · doi:10.1007/s13277-014-1845-9 · Cited by 124
Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
Kuo, C.-N., Liao, Y., Kuo, L., Tsai, H., Chang, W., & Yen, Y. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.08.023 · Cited by 113
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
Fanelli, G. N., Pozzo, C. A. D., Depetris, I., Schirripa, M., Brignola, S., Biason, P., Balistreri, M., Santo, L. D., Lonardi, S., Munari, G., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1117-2 · Cited by 129
Identification and characterization of RET fusions in advanced colorectal cancer
Le Rolle, A.-F., Klempner, S. J., Garrett, C. R., Seery, T., Sanford, E. M., Balasubramanian, S., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4325 · Cited by 109
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells
Lamba, S., Russo, M., Sun, C., Lazzari, L., Cancelliere, C., Grernrum, W., Lieftink, C., Bernards, R., Di Nicolantonio, F., & Bardelli, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.033 · Cited by 110
“KRAS mutations occur in approximately 20% of non-smallcell lung cancer (NSCLC) and 40% of colorectal cancer (CRC) cases, where they are associated with resistance to epidermal growth factor receptor (EGFR)-targeted therapies (Douillard et al., 2013; Karapetis et al., 2008; Linardou et al., 2008).”
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Perez-Gracia, J. L., Sanmamed, M. F., Bosch, A., Patiño-Garcia, A., Schalper, K. A., Segura, V., Bellmunt, J., Tabernero, J., Sweeney, C. J., Choueiri, T. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.005 · Cited by 108
“Subsequently, NRAS and additional downstream mutations, have been associated in retrospective analyses with lack of response to cetuximab [84,85].”
Self-citationERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
Kiavué, N., Cabel, L., Melaabi, S., Bataillon, G., Callens, C., Lerebours, F., Pierga, J., & Bidard, F. (2019) · Oncogene · doi:10.1038/s41388-019-1001-5 · Cited by 122
“Indeed, it has been shown that mutation in the RAS family is negative predictive biomarkers of response to anti-EGFR therapy in colorectal cancer [74].”
BackgroundMao, C., Wu, X.-Y., Yang, Z.-Y., Threapleton, D. E., Yuan, J.-Q., Yu, Y.-Y., & Tang, J.-L. (2015) · Scientific Reports · doi:10.1038/srep08065 · Cited by 107
Zhai, Z., Yu, X., Yang, B. J., Zhang, Y., Zhang, L., Li, X., & Sun, H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.033 · Cited by 119
Kawazoe, A., Shitara, K., Fukuoka, S., Kuboki, Y., Bando, H., Okamoto, W., Kojima, T., Fuse, N., Yamanaka, T., Doi, T., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1276-z · Cited by 106
“Recently, several reports have shown that other KRAS (exons 3 or 4) and NRAS mutations (exons 2– 4) occur in ~20% of mCRC patients with KRAS exon 2 wild-type tumors, which are associated with resistance to anti-EGFR therapy for mCRC [12-18].”
BackgroundMethodResultInfluentialMiyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 106
“More recent studies have found that resistance to anti-EGFR therapy can also be mediated by lower-frequency mutations in KRAS exon 3 or 4, or in NRAS exon 2, 3, or 4 [11,32,34].”
BackgroundPresent and future of metastatic colorectal cancer treatment: A review of new candidate targets
Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Sforza, V., Ciardiello, D., Napolitano, S., Corte, C. M. D., Morgillo, F., Raucci, A., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i26.4675 · Cited by 115
Troiani, T., Napolitano, S., Vitagliano, D., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., Ciardiello, D., Ciardiello, F., & Martinelli, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2181 · Cited by 104
Kirstein, M. M., Lange, A., Prenzler, A., Manns, M. P., Kubicka, S., & Vogel, A. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0032 · Cited by 112
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
“Similarly to cetuximab, the lack of efficacy in terms of OS is due to the absence of patients’ selection.(23)”
BackgroundPassiglia, F., Bronte, G., Bazan, V., Galvano, A., Vincenzi, B., & Russo, A. D. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.015 · Cited by 117
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.